Coeptis Therapeutics Holdings Inc (COEP) FinancialsCOEPCoeptis Therapeutics Holdings Inc

Coeptis Therapeutics Holdings Inc (COEP) generates its revenue primarily from Technology segment, which accounts for 100.0% of total sales, equivalent to $200.68K. Understanding this concentration is critical for investors evaluating how COEP navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Coeptis Therapeutics Holdings Inc maintains a gross margin of 65.76%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -230.64%, while the net margin is -188.26%. These profitability ratios, combined with a Return on Equity (ROE) of -142.32%, provide a clear picture of how effectively COEP converts its operational activities into shareholder value.

In the context of the broader market, COEP competes directly with industry leaders such as ANIX and COYA. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, COEP's gross margin of 65.76% stands against ANIX's N/A and COYA's 100.00%. Such benchmarking helps identify whether Coeptis Therapeutics Holdings Inc is trading at a premium or discount relative to its financial performance.

In Q4 2025, revenue remained flat YoY at $862,049. Net income dropped significantly to -$1,577,869 (-19% YoY), and EPS fell sharply to -0.29 (-69.47% YoY). Gross margin remained stable at 65.76%. Overall, the financials indicate weak growth and profitability.